A detailed history of Rtw Investments, LP transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Rtw Investments, LP holds 4,869,798 shares of IMCR stock, worth $158 Million. This represents 2.42% of its overall portfolio holdings.

Number of Shares
4,869,798
Previous 4,869,798 -0.0%
Holding current value
$158 Million
Previous $165 Million 8.14%
% of portfolio
2.42%
Previous 2.76%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$33.78 - $63.75 $38.8 Million - $73.3 Million
-1,149,843 Reduced 19.1%
4,869,798 $165 Million
Q1 2024

May 15, 2024

SELL
$60.14 - $75.36 $4.62 Million - $5.78 Million
-76,746 Reduced 1.26%
6,019,641 $391 Million
Q3 2023

Nov 14, 2023

BUY
$49.5 - $66.6 $3.3 Million - $4.45 Million
66,754 Added 1.11%
6,096,387 $316 Million
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $18.4 Million - $23.4 Million
379,690 Added 6.72%
6,029,633 $362 Million
Q1 2023

May 15, 2023

BUY
$46.12 - $65.71 $4.18 Million - $5.95 Million
90,621 Added 1.63%
5,649,943 $279 Million
Q4 2022

Feb 14, 2023

BUY
$45.51 - $65.08 $50.4 Million - $72.1 Million
1,107,839 Added 24.89%
5,559,322 $317 Million
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $17 Million - $26.2 Million
455,329 Added 11.39%
4,451,483 $209 Million
Q2 2022

Aug 15, 2022

BUY
$25.46 - $37.72 $54.4 Million - $80.6 Million
2,136,683 Added 114.91%
3,996,154 $149 Million
Q1 2022

May 16, 2022

BUY
$18.94 - $34.29 $11.6 Million - $21.1 Million
613,939 Added 49.29%
1,859,471 $55.6 Million
Q1 2021

May 14, 2021

BUY
$36.3 - $56.34 $45.2 Million - $70.2 Million
1,245,532 New
1,245,532 $50.1 Million

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.42B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Rtw Investments, LP Portfolio

Follow Rtw Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.